Prednisolone: Nursing Drug Guide, Adrenal Taper & Hold Rules

• Orapred — prednisolone sodium phosphate oral solution and orally disintegrating tablets (ODT)
• Prelone, Pediapred, Flo-Pred — oral solutions (various concentrations)
• Millipred — prednisolone tablets
• Multiple generic prednisolone tablets, oral solutions, and ODT products — verify mg per tablet or mL and salt (base vs sodium phosphate)
• Topical / local — prednisolone acetate eye drops (e.g. Pred Forte) and otic preparations are separate routes with systemic absorption possible per BNF

Institutional formularies and available strengths may vary. Use the product-specific prescribing information for the exact formulation dispensed.

Prednisolone is an active oral glucocorticoid (not a prodrug like prednisone). Nurses most often see it for:

• Asthma exacerbations — BNF: adults 40–50 mg once daily for at least 5 days; children 1–2 mg/kg daily (max per dose 40–60 mg) for up to 3 days or longer if necessary
• COPD exacerbation — BNF: 30 mg once daily for 5 days when increased breathlessness interferes with daily activities
• Inflammatory and autoimmune disorders — rheumatoid arthritis, lupus, polymyalgia rheumatica, giant cell arteritis, and other collagen-vascular conditions per BNF
• Ulcerative colitis / Crohn disease — oral induction doses with taper per prescriber; rectal foam, suppositories, or enemas for distal disease
• Allergic and dermatologic conditions, croup (pediatric), pneumocystis pneumonia adjunct in HIV (BNF), and other specialist-directed indications

Dose and duration depend on indication. Short burst courses still require taper planning when therapy exceeds a few days.

Prednisolone exerts predominantly glucocorticoid effects with minimal mineralocorticoid activity (BNF). It binds glucocorticoid receptors and modifies immune and metabolic responses:

• Anti-inflammatory — reduces cytokine-mediated inflammation
• Immunosuppressive — decreases lymphocyte function at higher doses; masks signs of infection
• Metabolic — increases gluconeogenesis, decreases carbohydrate tolerance, and can cause fluid retention and potassium loss
• Active drug — unlike prednisone, prednisolone does not require hepatic conversion for effect—relevant in severe hepatic impairment per BNF cautions

Dose depends on indication, age, and formulation. Always verify the signed order, product label, and institutional protocol. Examples from BNF—not a substitute for pharmacist or prescriber calculation.

Common oral courses (BNF)

Other BNF examples

• Rheumatoid arthritis (early disease): 7.5 mg daily
• Polymyalgia rheumatica / giant cell arteritis: 10–60 mg daily with long taper—many patients need ≥2 years
• COVID-19 requiring supplemental oxygen (when dexamethasone unavailable): 40 mg once daily for 10 days or until discharge if sooner

Taper

BNF states that after prolonged corticosteroid therapy, withdrawal must be gradual because abrupt stop can cause acute adrenal insufficiency, hypotension, or death. Any significant intercurrent illness, trauma, or surgery may require temporary dose increase or reintroduction per specialist guidance—coordinate with prescriber and pharmacy.

Renal and hepatic impairment: manufacturers advise caution; not specified in the reviewed prescribing information for detailed dose adjustments—verify current labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

• Right patient, drug, dose, route, time — and cumulative systemic steroid days
• Read full generic name — BNF documents prednisolone confused with propranolol (verify label and MAR)
• Active infection, immunosuppression risk, recent live vaccine exposure
• Glucose trend and diabetes history — anticipate hyperglycemia symptoms
• Blood pressure, fluid status, GI bleed risk, psychiatric history
• Confirm taper, continuation, or stress-dose plan at transitions of care
• Perform medication reconciliation for all glucocorticoid sources including inhaled steroids with systemic effect

Key interactions (verify current BNF / labeling)

Review full interaction profile in BNF before administration. Common nursing concerns include concurrent NSAIDs without gastroprotection (STOPP criteria in older adults), antidiabetic dose adjustments when glucose rises, and vaccines during immunosuppression.

Oral tablets / solution / ODT:

• BNF advises taking once-daily doses in the morning after breakfast when possible
• Oral solution — use an oral syringe; verify concentration (mg/5 mL) before drawing volume
• ODT — handle with dry hands; allow to dissolve on tongue per product labeling
• Do not crush or split unless product labeling supports it—ask pharmacy for swallowing difficulty

Rectal foam / suppositories / enema: administer per product instructions after bowel movement when indicated; systemic absorption can occur—monitor as for oral steroids.

Ophthalmic / otic: not interchangeable with systemic oral products—verify route on MAR.

Missed dose: not specified in the reviewed prescribing information—contact prescriber or pharmacist; do not double without guidance.

• Reduced inflammation — improved pain, joint swelling, or respiratory work of breathing depending on indication
• Stabilized allergic or autoimmune flare with prescriber-defined taper plan afterward
• Asthma/COPD burst: improved wheeze and work of breathing over 48–72 hours is typical clinical expectation—exact timeline not specified in the reviewed prescribing information
• Glucose may rise even when breathing improves—continue glucose monitoring

• Hypotension, dizziness, confusion, abdominal pain, or severe fatigue after missed doses or abrupt stop — possible adrenal crisis; escalate immediately
• New fever, productive cough, wound erythema, or hemodynamic changes on immunosuppressive doses — infection may be masked; urgent assessment
• Pharmacy label shows propranolol or another non-steroid while MAR orders prednisolone — do not administer; report error
• Facial swelling, bronchospasm, urticaria, or respiratory distress after dose — treat as anaphylaxis per protocol
• Acute psychosis, suicidal ideation, or severe mood change — notify prescriber urgently
• Signs of GI perforation in patients with inflammatory bowel disease — severe abdominal pain, rigidity, sepsis physiology
• Vomiting with abdominal pain in children on steroids — consider serious GI complication per clinical judgment

↔On a small screen, swipe or scroll sideways to see the full table.

Antidote: No specific antidote is listed in the reviewed prednisolone prescribing information.

Manage suspected overdose with supportive and symptomatic therapy per prescriber, pharmacist, and toxicology guidance. Monitor for hyperglycemia, hypertension, electrolyte shifts, psychiatric disturbance, and GI bleeding with large exposures.

Important: After prolonged therapy, do not abruptly withhold prednisolone because of concern for toxicity—coordinate a gradual taper with the prescriber to avoid adrenal crisis.

• Prednisolone vs propranolol — documented BNF safe-practice confusion; verify full generic name on prescription, label, and MAR
• Prednisolone vs prednisone — different prodrug/active profile and potency; duplicate therapy is common
• Prednisolone vs dexamethasone / hydrocortisone — potency and duration differ
• Sodium phosphate vs base — conversion and volume differ; confirm mg and mL on oral solutions
• Systemic vs topical eye drops — Pred Forte and similar are not for oral administration

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Vital signs, fluid balance, weight, and edema
• Blood glucose — capillary or laboratory per orders, especially in type 2 diabetes
• Signs of infection, wound healing, and mental status changes
• BNF baseline for long-term therapy: BP, weight, BMI, HbA1c, triglycerides, potassium, eye examination when prolonged
• HbA1c and cortisol per prescriber when indicated
• Pain assessment and functional response for inflammatory indications

Document

• Indication, dose, route, formulation, volume (if solution), and cumulative days on prednisolone
• Patient education on taper, sick-day rules, infection reporting, and vaccine restrictions
• Any refusal, missed doses, or intent to stop early—notify prescriber same shift

• Do not stop prednisolone suddenly without medical supervision—carry steroid treatment or emergency card if on prolonged therapy per local policy
• Report fever, sore throat, worsening cough, confusion, dizziness, severe weakness, or abdominal pain promptly
• Monitor blood glucose if diabetic; report persistent thirst, polyuria, or high home readings
• Avoid live vaccines during immunosuppressive doses; ask the care team before any new vaccine
• Take exactly as prescribed—finish short burst courses unless prescriber changes the plan
• Seek medical advice if exposed to chickenpox or measles while on corticosteroids per BNF

Do not give and contact the prescriber/pharmacist when:

After long-term therapy, holding a dose still requires prescriber input on taper—not silent omission.

Practice NCLEX-style clinical judgment practice for prednisolone using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), infection and glucose trends, BNF-aligned taper cloze, propranolol LASA judgment, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.